Lipopeptide compound for the treatment of pain disorder

The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Keywords: Pain - Lipopeptide
Patent Application number: null
Nat Commun. 2017 Nov 3;8(1):1314. doi: 10.1038/s41467-017-01403-9.



    Business Developper
    Anne COCHI
    Business Development Manager
    Patent filling date: 27-04-2017
    Rare disease: No
    Second indication: No

    You might also be interested in